Novo sues Lilly over GLP-1 ads; Tempus buys for $1.5B

Good morning, healthcare professional.

The pharmaceutical industry's most lucrative battleground just got a courtroom. Novo Nordisk has filed suit against Eli Lilly alleging deceptive advertising in the blockbuster GLP-1 market, while major consolidation continues with Tempus acquiring cancer diagnostics firm Personalis for $1.5 billion. Meanwhile, Bristol Myers Squibb is racing to build what it claims will be pharma's largest AI supercomputer, and Samsung Biologics pursues an $1.8 billion deal for Swiss peptide manufacturer PolyPeptide.

These developments signal intensifying competition across multiple fronts: legal warfare over market share, strategic M&A to capture precision medicine capabilities, and massive infrastructure investments in artificial intelligence. The moves reflect how pharmaceutical giants are simultaneously defending existing franchises while positioning for the next wave of innovation.

In today's healthcare digest:

• Novo Nordisk takes legal action against Eli Lilly over GLP-1 drug advertising practices
• Tempus expands oncology diagnostics portfolio with $1.5 billion Personalis acquisition
• Bristol Myers and Samsung Biologics make major AI and manufacturing investments
• Telehealth company faces patient safety allegations as compounders hold GLP-1 market position

Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising

Novo Nordisk has filed a lawsuit against Eli Lilly alleging deceptive advertising practices related to GLP-1 drugs. The legal action escalates competition in the multi-billion dollar weight loss and diabetes medication market.

Unpacked:

• The lawsuit targets advertising claims for GLP-1 medications, which have become one of pharma's most lucrative drug categories.
• Both companies compete directly in the rapidly expanding weight loss and diabetes treatment space worth billions annually.
• This legal battle could influence marketing strategies and competitive positioning across the entire GLP-1 category.

Tempus Acquires Personalis for $1.5 Billion

Tempus is acquiring cancer diagnostics company Personalis in a $1.5 billion deal. The acquisition expands Tempus's precision medicine and cancer testing capabilities in the oncology diagnostics space.

Unpacked:

• The deal represents significant consolidation in molecular diagnostics and genomic profiling for cancer treatment.
• Tempus gains expanded capabilities in personalized cancer care and data-driven therapeutic approaches.
• This acquisition positions Tempus to capture more of the growing precision oncology market.

Bristol Myers and Samsung Biologics Make Strategic Investments

Bristol Myers Squibb announced plans to build what it claims will be pharma's largest NVIDIA AI supercomputer for drug discovery. Separately, Samsung Biologics is pursuing an $1.8 billion acquisition of Swiss CDMO PolyPeptide.

Unpacked:

• Bristol Myers joins the pharmaceutical industry race to implement AI infrastructure for accelerated drug development.
• Samsung Biologics would gain significant peptide manufacturing capacity through the PolyPeptide acquisition.
• These moves reflect dual industry priorities: technological innovation through AI and expanded biologics manufacturing capabilities.

Telehealth Company Faces Patient Safety Allegations

A telemedicine company previously endorsed by Novo Nordisk is facing allegations from former employees that it prioritized profits over patient safety in prescribing weight loss drugs. Meanwhile, compounding pharmacies maintain a strong position in the GLP-1 market.

Unpacked:

• Former workers allege the telehealth provider emphasized revenue over appropriate patient screening and safety protocols.
• Compounding pharmacies continue capturing GLP-1 market share, creating ongoing challenges for major pharmaceutical manufacturers.
• These developments highlight regulatory and safety concerns in the rapidly expanding telehealth and weight loss medication space.

The Shortlist

• GSK shelved its chronic cough drug camlipixant after disappointing trial results, abandoning a treatment acquired in a $2 billion deal.

• Latigo Biotherapeutics outlined plans to go public with its pain drug pipeline targeting ion channels for non-opioid pain management.

• Novartis gained full FDA approval for Fabhalta in IgA nephropathy, expanding treatment options for the kidney disorder.

• FDA investigators continue focusing on a lettuce supplier as the source of a cyclospora parasite outbreak despite one faulty test result.